mTORC1/mTORC2 (dual inhibitor)

Class

highly selective, orally bioavailable, ATP-competitive dual inhibitor of mTOR kinase complexes 1 and 2, addressing the incomplete pathway blockade and AKT-reactivation resistance seen with mTORC1-only rapalogs

Pathway

dual mTORC1/2 blockade suppresses downstream PI3K/AKT/mTOR effectors (S6, 4E-BP1), producing apoptosis and cell-cycle arrest

mTOR is a kinase (an enzyme that adds phosphate groups to other proteins) that sits at the center of a signaling pathway called PI3K/AKT/mTOR, which cells use to decide whether to grow, divide, or survive based on nutrient and growth-factor cues. mTOR functions within two distinct multiprotein complexes, mTORC1 and mTORC2, each with different regulatory partners and downstream substrates. Many cancers exploit this pathway through mutations or amplifications, driving unchecked proliferation and resistance to cell death. Early mTOR-targeted therapies (rapalogs) inhibit only mTORC1, and this partial blockade can paradoxically activate AKT, an upstream kinase, through a feedback loop, undermining the intended antitumor effect. A dual, ATP-competitive inhibitor blocks the catalytic activity of mTOR itself, engaging both complexes simultaneously and closing this escape route, producing more complete suppression of the pathway's growth and survival signals. Downstream, this leads to reduced phosphorylation of proteins that control translation and cell-cycle progression, tipping cancer cells toward apoptosis (programmed cell death) and growth arrest. This approach is relevant across a range of solid tumors and hematologic malignancies where dysregulated PI3K/AKT/mTOR signaling supports tumor growth, particularly in settings where rapalog-based therapy alone has proven insufficient.